Braveheart Bio Targets $1.2 Billion Valuation in IPO
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
Archive
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
The executive-search firm is adding an AI-focused recruiting team with startup customers.
The rocket and satellite company entered Nasdaq trading at a valuation above $1.7 trillion.
The ChatGPT maker joined Anthropic in a high-stakes race to bring frontier AI companies to public markets.
The Claude developer moved ahead of OpenAI as frontier AI companies prepare for public scrutiny.
The AI chipmaker nearly doubled its offering price as investors sought another route into compute infrastructure.